[Combination of profundaplasty and pharmacotherapy in stage III/IV peripheral arterial occlusive disease].
This prospective randomized study shows that adjuvant 3-week i.v. PGE1 treatment substantially improves the short-term results in patients undergoing profundaplasty. Compared with placebo, PGE1 approximately doubles the number of patients returning from stage III/IV to stage IIb of PAOD. Five years after surgery, the outcome with respect to limb salvage and patient survival rate was significantly better in patients additionally treated with PGE1.